Keros Therapeutics Inc expected to post a loss of $1.37 a share - Earnings Preview

Keros Therapeutics

28/02/2024 11:02

* Keros Therapeutics Inc  KROS.OQ   KROS.O  is expected
to show no
change in quarterly revenue when it reports  results on March 1
(estimated) for the period ending December 31 2023
    * 
    * ​LSEG's mean analyst estimate for Keros Therapeutics Inc
is for
a loss of $1.37 per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 11 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Keros
Therapeutics Inc is $85.00​, above​ its last closing price
of $70.00. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2023  -1.34       -1.35      -1.33     Beat    1.3
 Jun. 30 2023  -1.33       -1.34      -1.27     Beat    5.1
 Mar. 31 2023  -1.13       -1.12      -1.26     Missed  -12.2​
 Dec. 31 2022  -1.08       -1.10      -1.09     Beat    0.7
 ​​Sep.        -1.23       -1.23      -0.92     Beat    25.3
 30 2022                                                
 Jun. 30 2022  -1.05       -1.06      -1.13     Missed  -6.8​
 Mar. 31 2022  -0.86       -0.86      -1.01     Missed  -17.1
 Dec. 31 2021  -0.97       -0.92      -0.30     Beat    67.3
 This summary was machine generated February 28 at 11:02 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)